CME: IBS-D: What to Do when Typical Treatment Methods Fail

IBS-D: What to Do when Typical Treatment Methods Fail

IBS-D: What to Do when Typical Treatment Methods Fail
This interactive online case study focuses on treatment considerations for patients who have IBS-D that is resistant to therapy.

Available credits: 0.50

Time to complete: 30 minutes


Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    Patients with IBS-D often try multiple medications that fail to treat their symptoms. IBS has a heterogeneous pathogenesis, and there are no specific algorithms for treatment subtypes. In this activity, clinicians will learn treatment options to consider for patients with IBS-D in whom some previous therapies have failed.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Commercial Support, The Omnia-Prova Education Collaborative (TOPEC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TOPEC resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Darren M. Brenner, MD, AGAF, has disclosed that he has received consulting fees from Allergan/Ironwood Pharmaceuticals; AstraZeneca; Salix Pharmaceuticals, Inc.; and Synergy Pharmaceuticals Inc. and has served on the speakers bureaus for Daiichi Sankyo, Inc. and Shionogi Inc.


    • Sean T. Barrett has nothing to disclose.
    • Carole Drexel, PhD, CHCP, has nothing to disclose.
    • Mary J. Krey has nothing to disclose.
    • Brian P. McDonough, MD, FAAFP, has nothing to disclose.
    • Wendee Theilemann has nothing to disclose.

    Disclosure of Unlabeled Use
    This CME activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products.

    Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: antidiarrheal agents, cognitive behavioral therapy/hypnotherapy, diet modification, tricyclic antidepressants, IBgard, ondansetron, probiotics, bile acid sequestrants (colestipol), antispasmodic agents, peppermint oil.

  • Intended Audience

    The intended audience for this activity is gastroenterologists and primary care providers.

  • Learning Objectives

    After completing this activity, the participant will be better able to:

    • Explain considerations in selecting effective treatment for IBS-D, including the role of microbiota management
    • Employ patient-clinician communication strategies that encourage patients to share and describe their symptoms
  • Accreditation and Credit Designation Statements

    This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of The Omnia-Prova Education Collaborative (TOPEC) and MedEdCom. TOPEC is accredited by the ACCME to provide continuing medical education for physicians.

    The Omnia-Prova Education Collaborative, Inc. designates this enduring material for a maximum of .5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider

    This activity is jointly provided by The Omnia-Prova Education Collaborative (TOPEC) and MedEdCom.

  • Commercial Support

    This activity is supported by an independent educational grant from Salix Pharmaceuticals, Inc.

  • System Requirements

    Our site requires a computer, tablet or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/cable). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Internet Explorer, Microsoft Edge, Chrome, Firefox or Safari. Users accustomed to IE8, IE9 IE10 are advised to update their browsers for the best experience.

Facebook Comments

Sign up for the Prova Education newsletters.

Better education for a better you.

* Required

We’re glad to see you’re enjoying Prova Education…
but how about a more personalized experience?

Register for free